1. Pink Sheet
  2. >>Legislation

US FDA Right To Try Policy: For Now, Defer Questions To Sponsors, Bill Text

 
• By Derrick Gingery

Agency tells staff that it should refer patient questions about the law to the drug sponsor, while sponsors should be told to read the statute if they inquire about it.

White House

Patients, physicians, and sponsors looking for more information about the newly enacted Right to Try law will not find much immediate help at the US FDA.

The agency does not want staff answering questions about or relating to the newly enacted right to try law. Center for Drug Evaluation and Research Director Janet Woodcock told employees in a May 30 email sent shortly after President Trump signed the 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.